For: | Zeng ZM, Mo N, Zeng J, Ma FC, Jiang YF, Huang HS, Liao XW, Zhu GZ, Ma J, Peng T. Advances in postoperative adjuvant therapy for primary liver cancer. World J Gastrointest Oncol 2022; 14(9): 1604-1621 [PMID: 36187393 DOI: 10.4251/wjgo.v14.i9.1604] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v14/i9/1604.htm |
Number | Citing Articles |
1 |
Jiageng Guo, Xinya Jiang, Jing Lian, Huaying Li, Fan Zhang, Jinling Xie, Jiagang Deng, Xiaotao Hou, Zhengcai Du, Erwei Hao. Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway. Frontiers in Cell and Developmental Biology 2024; 12 doi: 10.3389/fcell.2024.1431423
|
2 |
Hui Shao, Jingyan Chen, Ali Li, Lili Ma, Yongzhi Tang, Huazhong Chen, Yongping Chen, Junyan Liu. Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway. Applied Biochemistry and Biotechnology 2023; 195(8): 5217 doi: 10.1007/s12010-023-04511-z
|
3 |
Yanyan Ye, Ying Wang, Haoqian Xu, Fengming Yi. Network meta-analysis of adjuvant treatments for patients with hepatocellular carcinoma after curative resection. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02955-5
|
4 |
Rui Luo, Chongkai Fang, Chuyao Chen, Ying Zhang, Ruiwei Yao, Jinan Wang, Hanqian Shi, Kunliang Feng, Mingli Hu, Chong Zhong. Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1212116
|
5 |
Jeng-Shiun Du, Shih-Hsien Hsu, Shen-Nien Wang. The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma. Cancers 2024; 16(7): 1422 doi: 10.3390/cancers16071422
|
6 |
Luyang Wang, Le Tong, Zecheng Xiong, Yi Chen, Ping Zhang, Yan Gao, Jing Liu, Lei Yang, Chunqi Huang, Gaoqi Ye, Jing Du, Huibiao Liu, Wei Yang, Ying Wang. Ferroptosis-inducing nanomedicine and targeted short peptide for synergistic treatment of hepatocellular carcinoma. Journal of Nanobiotechnology 2024; 22(1) doi: 10.1186/s12951-024-02808-7
|
7 |
Xiaoying Xu, Yu Liu, Yanyan Liu, Yahan Yu, Mingqi Yang, Ligong Lu, Leung Chan, Bing Liu. Functional hydrogels for hepatocellular carcinoma: therapy, imaging, and in vitro model. Journal of Nanobiotechnology 2024; 22(1) doi: 10.1186/s12951-024-02547-9
|
8 |
Yichen Peng, Xia Wu, Yurong Zhang, Yue Yin, Xianglin Chen, Ding Zheng, Jing Wang. An Overview of Traditional Chinese Medicine in the Treatment After Radical Resection of Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2023; : 2305 doi: 10.2147/JHC.S413996
|
9 |
Ming‐Da Wang, Xue‐Jun Xu, Ke‐Chun Wang, Yong‐Kang Diao, Jia‐Hao Xu, Li‐Hui Gu, Lan‐Qing Yao, Chao Li, Guo‐Yue Lv, Tian Yang. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities. Cancer Science 2024; 115(7): 2159 doi: 10.1111/cas.16194
|
10 |
Yi-Hao Yen, Fang-Ying Kuo, Hock-Liew Eng, Yueh-Wei Liu, Chee-Chien Yong, Wei-Feng Li, Chih-Chi Wang, Chih-Yun Lin, Tyng-Yuan Jang. Tumor necrosis as a predictor of early tumor recurrence after resection in patients with hepatoma. PLOS ONE 2023; 18(11): e0292144 doi: 10.1371/journal.pone.0292144
|
11 |
Bowen Men, Huzhe Cui, Zhezhu Han, Xiuying Jin, Qiang Xu, Yongmin Jin, Zhengri Piao, Songnan Zhang. Evaluation of the efficacy of transarterial chemoembolization combined with microwave ablation followed by adjuvant therapy in patients with hepatocellular carcinoma. Frontiers in Immunology 2024; 15 doi: 10.3389/fimmu.2024.1337396
|
12 |
Walaa Abdelhamed, Mohamed El-Kassas. Hepatocellular carcinoma recurrence: Predictors and management. Liver Research 2023; 7(4): 321 doi: 10.1016/j.livres.2023.11.004
|